CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

Products

back to search results

CD79a [JCB117]

Product information References Bioinformatics Documents
Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: JCB117
Host: Mouse
Isotype: IgG1
Application: Flow cytometry (FC), Immunofluorescence (IF), Immunohistochemistry (IHC)
Application notes: 100-300
Conjugation Type: Unconjugated
Lightchain type: Kappa
Reactivity: Human
General notes: Localization: membrane.
Buffer: citrate pH6.0
UNSPSC code: 12352203

CD79 consist of two proteins, CD79a (mb-1) and CD79b (B29). CD79a recognizes the Ig-alpha protein, and CD79b recognizes the Ig-beta protein of the B-cell antigen component of the B-lymphocyte antigen receptor. The expression of CD79 precedes immunoglobulin (Ig) gene, heavy-chain gene rearrangement and CD20 expression. In precursor B cells, the CD79 protein chains are already expressed in the cytoplasm (CyCD79). Surface expression of CD79 begins at the pro-B cell stage and persists throughout the B-cell differentiation, and continues presents on plasma cells. CD79a is an excellent marker for identification of normal and neoplastic B lymphocytes. This CD79a antibody has been validated by the 9th International Conference on Human Leukocyte Differentiation Antigens (HLDA9). (Shipping Cost: €200.00)

CD79a [JCB117]

CD79 consist of two proteins, CD79a (mb-1) and CD79b (B29). CD79a recognizes the Ig-alpha protein, and CD79b recognizes the Ig-beta protein of the B-cell antigen component of the B-lymphocyte antigen receptor. The expression of CD79 precedes immunoglobulin (Ig) gene, heavy-chain gene rearrangement and CD20 expression. In precursor B cells, the CD79 protein chains are already expressed in the cytoplasm (CyCD79). Surface expression of CD79 begins at the pro-B cell stage and persists throughout the B-cell differentiation, and continues presents on plasma cells. CD79a is an excellent marker for identification of normal and neoplastic B lymphocytes. This CD79a antibody has been validated by the 9th International Conference on Human Leukocyte Differentiation Antigens (HLDA9).